Twist Bioscience Corp
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$77.7M
- Total assets
- $641.9M
- Market cap
- $4.3B
- Gross margin
- 50.7%
- Operating margin
- -36.2%
- Net margin
- -20.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $376.6M
- Cost of revenue
- $185.6M
- Gross profit
- $191.0M
- Operating expenses
- $327.3M
- Operating income
- -$136.3M
- Income tax
- $719.0K
- Net income
- -$77.7M
- EPS (basic)
- $-1.30
- EPS (diluted)
- $-1.30
Balance sheet
- Total assets
- $641.9M
- Current assets
- $333.0M
- Total liabilities
- $168.9M
- Current liabilities
- $91.4M
- Shareholders’ equity
- $473.0M
Cash flow
- Operating cash flow
- -$47.6M
- Investing cash flow
- -$24.8M
- Financing cash flow
- $28.5M
- Net cash flow
- -$43.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.3B
- EPS (diluted)
- $-1.3
- Shares outstanding
- 61.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 31, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $77.7M.
- Revenue grew 185% from FY2021 to FY2025.
- Gross margin of 50.7%, net margin -20.6%.
- Trading 5% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review Twist Bioscience Corp.
Write a review
News about Twist Bioscience Corp
News & sentiment via Polygon.io
